Wanbang Pays $39 Million for China Rights to Renal Disease Treatments

Wanbang Biopharma, a subsidiary of Shanghai Fosun Pharma, obtained China rights for two End-Stage-Renal-Disease treatments from Rockwell Medical of the US. Wanbang agreed to pay Rockwell $39 million in upfront plus regulatory and revenue milestone payments. Rockwell will supply the products. The two drugs are Triferic and Calcitriol. Triferic is Rockwell’s proprietary iron replacement and hemoglobin maintenance drug for treating anemia. Calcitriol, a generic product, is an active vitamin D injection for treatment of secondary hyperparathyroidism in dialysis patients. More details..... Stock Symbols: (SHA: 600196; HK: 02196) (NSDQ: RMTI) Share this with colleagues: // //